FDA Grants Approval for Acyclovir ANDA213951 by Vistapharm
The FDA has granted approval for the ANDA213951 application for Acyclovir submitted by Vistapharm LLC.
Published: July 9, 2026
Updated: July 9, 2026
Author: Humanexa Intelligence
Therapeutic area: Infectious Disease / Antiviral
Asset: Acyclovir
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Acyclovir
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Acyclovir ANDA213951 by Vistapharm is significant as it introduces a new competitor in the antiviral market. This could lead to shifts in pricing and market dynamics, necessitating strategic reassessment by existing players in the Acyclovir space.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Vistapharm and competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.